- MS, Bioengineering, IQS Barcelona
- BA, Chemistry, UAB Barcelona
- Current Affiliation
- Social Media
Jordi B. is an early scientist fascinated by the way diseases can be modeled in a plate in order to screen libraries of compounds and find novel drugs that can have a positive impact in people’s lives.
He obtained his Bachelor’s degree in Chemistry with specialization in Biological Chemistry from the Autonomous University of Barcelona (UAB). During his bachelor’s thesis, he collaborated for a year the Bioinorganic Chemistry group of UAB in the synthesis and characterization of a cooper metallodrug and its functionalization in a novel dendritic multimodal nanometric platform in order to enhance its drug delivery.
Amazed by the way biological entities could be used to model diseases, he pursued his Master’s degree in Bioengineering in the Institut Químic de Sarrià (IQS), where he discovered the drug discovery and development field. Afterwards, he joined the ZeCardio Therapeutics team, where he worked in the set-up and validation of an in vivo doxorubicin-induced cardiotoxicity model in zebrafish and in vitro cellular model for the phenotypical screening of potential cardioprotective drugs. In parallel, he worked in the generation and validation of new models of cardiomyopathies and cardioregeneration using the CRISPR/Cas9 gene editing technology , either in cells and zebrafish, with the aim of realizing further screening campaigns.
Captivated by the drug discovery and development field and the new paradigm provided by the biomolecular condensate biology framework in diseases, he joined the talented Dewpoint Therapeutics team.